HAE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Haemonetics Corp (HAE) is not a strong buy for a beginner, long-term investor at this moment. While the stock has some positive catalysts such as bullish moving averages and analyst optimism about its NexSys system, the lack of strong proprietary trading signals, neutral trading sentiment, and weak technical indicators suggest a 'hold' stance. The stock's near-term price trend is not compelling enough for immediate entry.
The MACD is negatively expanding (-0.147), indicating bearish momentum. RSI is neutral at 51.181, and the stock is trading below its pivot level of 75.873. However, moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting some long-term strength. Key support is at 71.154, and resistance is at 80.593.
Analysts have raised price targets recently, with Mizuho increasing it to $85, citing strong performance of the NexSys system and a healthy end-market for intravenous immunoglobulin products. Bullish moving averages also indicate long-term potential.
MACD is bearish, and the RSI is neutral, showing no clear upward momentum. The stock's short-term trend suggests a potential decline of -1.1% in the next day and -0.58% in the next month. No recent news or congress trading activity adds to the lack of immediate positive catalysts.
No financial data available for analysis.
Analyst sentiment is mixed but leans positive. Mizuho and Citi raised price targets recently, while others like Barrington and JPMorgan lowered targets due to profitability concerns and mixed Q4 results. Overall, the stock has an Outperform rating from multiple analysts.
